ABSTRACT Nonsteroidal anti-inflammatory drugs and sulfinpyrazone compete dose-dependently with arachidonate for binding to platelet cyclooxygenase. Such a process closely follows systemic plasma drug concentrations and is reversible as a function of drug elimination. Peak inhibition and extent of its reversibility at 24 hr varies consistently with individual pharmacokinetic profile. Inhibition of platelet cyclooxygenase activity by these agents is associated with variable effects on prostaglandin (PG) synthesis in the gastric mucosa and the kidney. Aspirin acetylates platelet cyclooxygenase and permanently inhibits thromboxane (TX) A2 production in a dose-dependent fashion when single doses of 0. 1 to 2.0 mg/kg are given. Acetylation of the enzyme by low-dose aspirin is cumulative on repeated dosing. The fractional dose of aspirin necessary to achieve a given level of acetylation by virtue of cumulative effects approximately equals the fractional daily platelet turnover. Serum TXB2 measurements obtained during long-term dosing with 0.11, 0.22, and 0.44 mg/kg aspirin in four healthy subjects could be fitted by a theoretical model assuming identical acetylation of platelet (irreversible) and megakaryocyte (reversible) cyclooxygenase. For a given dose within this range, both the rate at which cumulative acetylation occurs and its maximal extent largely depend upon the rate of platelet turnover. Continuous administration of low-dose aspirin (20 to 40 mg/day) has no statistically significant effect on urinary excretion of either 6-keto-PGFl,a or 2,3-dinor-6-keto-PGF ,t, i.e., indexes of renal and extrarenal PGI2 biosynthesis in vivo. Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials. Circulation 72, No. 6, 1177No. 6, -1184No. 6, , 1985 PLATELET CYCLOOXYGENASE or prostaglandin (PG) H synthase (i.e., the enzyme that converts arachidonate released from membrane phospholipids into PG endoperoxides) is the target of several antiplatelet agents that can reversibly or irreversibly block the activity of the enzyme by competing with the substrate or permanently altering the active site, respectively.' Such drugs belong to the class of so-called nonsteroidal anti-inflammatory agents (e.g., indomethacin, aspirin), but also include a uricosuric agent, i.e., sulfinpyrazone. This article will review the available information on platelet cyclooxygenase inhibition, as derived from human studies in health and disease, and present novel findings related to the mechanism of and variables affecting cumulative inhibition of the enzyme by low-dose aspirin. Assessment of human platelet cyclooxygenase activity. Platelet PGH synthase levels can be determined with an immunoradiometric assay.2 However, PGH synthase immunoreactivity is not influenced by inactivation of the enzyme with aspirin.2 Similarly, a dissociation between platelet PGH synthase concentration and activity has been shown in uremic patients.3 Also, the enzyme can be measured by its ability to interact selectively with (acetyl-3H) aspirin and undergo a site-specific acetylation reaction, giving rise to (acetyl-3H) PGH synthase.4 Inactivation of platelet cyclooxygenase by aspirin in vivo can be measured as a reduction in the ability of (acetyl-3H) aspirin to acetylate the enzyme in washed platelets in vitro.5
PLATELET CYCLOOXYGENASE or prostaglandin (PG) H synthase (i.e., the enzyme that converts arachidonate released from membrane phospholipids into PG endoperoxides) is the target of several antiplatelet agents that can reversibly or irreversibly block the activity of the enzyme by competing with the substrate or permanently altering the active site, respectively.' Such drugs belong to the class of so-called nonsteroidal anti-inflammatory agents (e.g., indomethacin, aspirin), but also include a uricosuric agent, i.e., sulfinpyrazone. This article will review the available information on platelet cyclooxygenase inhibition, as derived from human studies in health and disease, and present novel findings related to the mechanism of and variables affecting cumulative inhibition of the enzyme by low-dose aspirin.
Assessment of human platelet cyclooxygenase activity. Platelet PGH synthase levels can be determined with an immunoradiometric assay.2 However, PGH synthase immunoreactivity is not influenced by inactivation of the enzyme with aspirin.2 Similarly, a dissociation between platelet PGH synthase concentration and activity has been shown in uremic patients.3 Also, the enzyme can be measured by its ability to interact selectively with (acetyl-3H) aspirin and undergo a site-specific acetylation reaction, giving rise to (acetyl-3H) PGH synthase.4 Inactivation of platelet cyclooxygenase by aspirin in vivo can be measured as a reduction in the ability of (acetyl-3H) aspirin to acetylate the enzyme in washed platelets in vitro.5
In the vast majority of studies assessing pharmacologic inhibition of platelet cyclooxygenase enzyme activity was measured ex vivo by quantitative analysis of the main product(s). These analyses may include measurement of (1) thromboxane (TX) A2-like biological activity released by exogenous arachidonate in platelet-rich plasma (PRP),6 (2) malondialdehyde (MDA) production in PRP stimulated with N-ethyl-malei-1177 mide,7 and (3) TXB2 production in whole blood,8 agonist-stimulated PRP,9' 10 or bleeding-time blood.1' The latter have gained wider acceptance as indicators of platelet inhibition because of the more accurate and specific determination of TXB2 by radioimmunoassay (RIA) or gas chromatography/mass spectrometry (GC/MS). These methods assess the capacity of platelets to synthesize TXB2 in response to native or exogenously added stimuli and by no means reflect the actual production rate of TXB2 in vivo. 12 Such platelet-specific indexes can be used appropriately in pharmacologic studies in which drug-induced changes in cyclooxygenase or TX synthase are being investigated.
In our studies, we have used serum TXB2determina-tions as a reflection of thrombin-induced platelet TXA2 production during whole blood clotting.8 Serum levels of this eicosanoid averaged 300 ± 108 ng/ml (mean ± SD) in a group of 177 healthy subjects, with no statistically significant differences between men and women.'3 In this study, no statistically significant correlation was found between serum TXB2 and any of the continuous variables examined (age, body mass index, blood pressure, cigarette smoking, and serum cholesterol, triglyceride, and glucose) except for the number of platelets. Upon repeated blood sampling on successive days in healthy subjects, the intrasubject variability in serum TXB2 determinations averaged 14 ± 5%,1' a value allowing accurate determination of marginal inhibition of enzyme activity. Consistent results have been reported from different laboratories, whether serum TXB2 was measured by RIA '46 or GC/MS. 17 The dinor metabolite of TXB2 is the most abundant urinary derivative of systemically administered radioactive TXB2 in man,'8 and it largely reflects systemic (extrarenal) TXB2 synthesis in vivo. 12 The relative contribution of platelet and extraplatelet sources to urinary 2,3-dinor-TXB2 remains to be determined under pathophysiologic conditions. The finding that daily dosing with 20 mg aspirin can reduce urinary 2,3-dinor-TXB2 excretion by 67% in healthy subjects9 suggests that it may represent primarily platelet TXB2 production under physiologic conditions. Reversible inhibition of platelet cyclooxygenase. Nonsteroidal anti-inflammatory drugs (with the exception of aspirin) and sulfinpyrazone compete dose dependently with arachidonate for binding to cyclooxygenase. Such a process closely follows systemic plasma drug concentrations and is reversible as a function of drug elinination. The extent and duration of inhibition of human platelet cyclooxygenase activity after a single dose of each of several of the currently available nonsteroidal anti-inflammatory drugs is detailed in ta- 1178 CIRCULATION these agents is associated with variable effects on PG synthesis in the gastric mucosa and the kidney.23 Such a differential pattern of inhibition may account for the diverse incidence of gastric and renal side effects associated with long-term use of cyclooxygenase inhibitors. One clear example of tissue-selective inhibition of cyclooxygenase activity is provided by sulindac and sulfinpyrazone. We have previously shown that sulindac does not inhibit renal PG synthesis in man. 19 This property is probably related to reoxidation of the active sulfide metabolite to its prodrug form within the kidney.24 Sulindac and sulfinpyrazone share the following pharmacokinetic and pharmacodynamic features: (1) the major biotransformations involve valence changes at the sulfur atom, (2) inhibition of cyclooxygenase activity is dependent on reduction to an active sulfide metabolite, and (3) the sulfide metabolite is not detected in urine after oral dosing of the prodrug. Sulfinpyrazone, similar to sulindac, does not inhibit renal cyclooxygenase activity when given to healthy subjects at a dosage (200 mg qid for 7 days) that significantly reduces platelet TXB2 production2' and urinary 2,3-dinor-6-keto-PGFla excretion,22 i.e., that reducing cyclooxygenase activity at platelet and vascular sites.12 The finding of a selective sparing of renal cyclooxygenase activity by sulfinpyrazone is consistent with the absence of short-term effects on glomerular filtration rate both in healthy subjects25 and patients with myocardial infarction. 26 Irreversible inactivation of platelet cyclooxygenase. Aspirin selectively acetylates the hydroxyl group of a single serine residue within the polypeptide chain of PGH2 synthase, thereby inactivating the enzyme.27 28 The serine side chain is probably located near the active site of the enzyme. As a consequence of this acetylation, the cyclooxygenase activity (arachidonate PGG2) of the enzyme is lost, while the peroxidase activity (PGG2 -* PGH2) is unaffected. cyclooxygenase activity, as reflected by TXB2 generation in serum measured after daily administration of 20 mg aspirin for 3 days, is illustrated in figure 2 as a percentage of basal activity before drug in the same subject. Serum TXB2 was reduced to 46% of control 60 min after the first dose, to 53% after the second dose, and to 43% after the third dose, with a similar time course. Given a 14% intrasubject coefficient of variation in serum TXB2 determinations in our laboratory,"4 the data presented in figure 2 = 12, p < .001) between the time interval necessary to achieve steady inhibition with long-term dosing and percentage inactivation of platelet cyclooxygenase after the first dose is shown in figure 4 . Each set of experimental data could be fitted by a theoretical model assuming that (1) aspirin acetylates platelet as well as megakaryocyte cyclooxygenase, (2) the two enzymes are equally sensitive to aspirin, (3) synthesis of the enzyme de novo occurs within 24 hr in megakaryocytes but not in platelets, and (4) platelets with acetylated and those with unacetylated cyclooxygenase have a similar life span. As shown in figure 5 , which illustrates results of three monthly experiments performed in the same subject, the computer-simulated pattern of inhibition closely matched the experimental data obtained at three dose levels. As an average, the two sets of data (computer-generated vs actual measurements of serum TXB2) did not differ from each other by a greater interval than the intrasubject coefficient of variation for the method.
In view of the above findings and of recent studies of Pedersen and appears likely that platelet life span represents a major variable affecting cumulative inhibition within this particular dose range. For a given dose, both the rate at which cumulative acetylation occurs and its maximal extent would essentially depend on the rate of platelet turnover and dosing interval.
Although the long-lasting suppression of TXA2-related platelet function by aspirin has been disputed on the basis of studies using pairs of aggregating agents, 10 the likely occurrence of this phenomenon in vivo is suggested by the positive results (>50% reduction in thrombotic events) of three clinical trials of once-daily dosing: a study of 160 mg in patients on hemodialysis,30 one of 324 mg in men with unstable angina,3' and one of 100 mg in patients with aortocoronary bypass.32 These results are consistent with the hypothesis that the antithrombotic effect of aspirin is largely or entirely related to irreversible inactivation of platelet cyclooxygenase and consequent suppression of TXA2-related platelet function. Further support for this contention derives from recent studies of Steele et al. 33 demonstrating that low-dose aspirin (1 mg/kg/day) is as effective as high-dose aspirin (20 mg/kg/day) combined with dipyridamole in preventing platelet deposition and mural thrombus formation after arterial balloon angioplasty in pigs. Although mechanisms other than acetylation of platelet cyclooxygenase may be operative after doses of aspirin of 10 to 20 mg/kg, the likelihood of this occurring at doses 10 to 20 times lower is limited by the stoichiometry of the acetylation reaction4 and its dose dependence in vivo.5 11
Is low-dose aspirin a selective inhibitor of platelet cyclooxygenase? Dissociation of the vascular from the platelet inhibiting effects of aspirin has been attempted on the assumption that intact PGI2 production might enhance the antithrombotic efficacy of the drug. Although probably not serving the role of a circulating antiplatSlet hormone, as originally proposed, PGI2 may still be important in the local modulation of platelet-endothelial interactions, particularly in patients with severe atherosclerosis and platelet activation. 34 Complete separation of platelet-inhibiting from vascular effects of aspirin can not be demonstrated after single doses.",13 However, continuous administration of aspirin in low doses (20 to 40 mg/day) has no statistically significant effects on urinary excretion of either 6-keto-PGFi 14 or 2,3-dinor-6-keto-PGF ,'9two indexes of renal and extrarenal PGI2 biosynthesis in vivo. 12 Inasmuch as the cumulative nature of aspirin-induced inhibition of cyclooxygenase activity is a function of the different rates of daily acetylation and turnover of the enzyme (cell turnover or synthesis de novo), careful consideration should be given to the possibility of variable effects of the drug when pathologic processes affect platelet and/or endothelial behavior. Thus, enhanced platelet turnover and/or endothelial damage might decrease the effectiveness and/or selectivity of low doses of aspirin.
De Caterina et al. 36 have reported that in patients recovering from myocardial infarction, low-dose aspirin (0.4 mg/kg/day) persistently inhibits platelet cyclooxygenase activity and TXA2-dependent platelet function over 1 month of therapy without significantly reducing urinary 6-keto-PGF, excretion. In contrast, Weksler et al. 3 have reported evidence for a significant cumulative inhibition of vascular PGI2 synthesis in atherosclerotic patients given 20 mg aspirin daily for 7 days. This study showed that there was a cumulative inhibition of maximal production of PGI2 ex vivo in vascular tissue, but that synthesis was 50% preserved. 37 This may indicate that sufficient reserve exists, that urinary 6-keto-PGF , or 2,3-dinor-6-keto-PGF, might not be depressed, and that sufficient PGI2 for local modulation of platelet function might persist. The long-term effects of intermittent aspirin regimens38 have not been explored, although evidence exists that they may effectively abolish platelet TXA2 production in healthy subjects.8 On theoretical grounds, it appears that the alleged benefit of giving a single fully effective dose (2 to 3 mg/kg) every 2 or 3 days might be offset by the profound and long-lasting inhibition of vascular PGI2 production after each dose. 15 35 An alternative regimen of 40 mg every 48 hr has been proposed recently.39 However, it does not appear that this regimen offers any appreciable advantage with respect to sparing venous PGI2 production when compared with the daily administration of the same dose.
Is selective inhibition of platelet cyclooxygenase activity by low-dose aspirin clinically important? The observation that aspirin can exert an antithrombotic effect when given in a dose that largely suppresses vascular PGI2 production40 and a critical appraisal of its role in platelet-vessel wall homeostasis4' have raised skepticism on the clinical relevance of sparing extraplatelet sites of cyclooxygenase activity. To the extent that PGI2 biosynthesis is enhanced in patients with severe atherosclerosis, possibly as a consequence of platelet interactions with endothelium or other vascular insults,34 preservation of the capacity of the vessel wall to produce this natural platelet-inhibitory compound would be desirable in the setting of platelet activation in vivo. Moreover, aspirin-induced reduction of PGI2 production in the gastric mucosa42 and in glomeruli43 has been CIRCULATION 1182 proposed to contribute importantly to gastric and renal side effects, respectively, that are associated with long-term use of the drug at high dosage.
Whether a selective sparing of extraplatelet cyclooxygenase activity by low-dose aspirin will result in increased antithrombotic efficacy, fewer toxic reactions, or both remains to be established in prospective clinical trials.
